Data as of Aug 29
| +0.0112 / +1.14%|
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +253.54% increase from the last price of 0.99.
The current consensus among 2 polled investment analysts is to Buy stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.